comparemela.com

Page 51 - ஆரீட News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investorideas com - Solar Stock News: Solar Integrated Roofing (OTC: $SIRC) Expands Nationwide with Binding LOI to Acquire Cornerstone Construction, a Leading Southeast Roofing and Solar Solutions Provider

Crunchfish enrolled to leading international payment network s partner program

Vision Lithium Expands Sirmac Lithium Project

Vision Lithium Expands Sirmac Lithium Project News provided by Share this article Share this article Company or Vision Lithium ) is pleased to report that it has staked 131 claims adjacent to its 100% owned Sirmac lithium property Northwest of Chibougamau, Quebec. The Sirmac property is now comprised of 155 map-staked claims covering 7,760 hectares (77 km 2). The property is located approximately 200 kilometres South of the Whabouchi lithium mine and 180 km by road Northwest of Chibougamau, Quebec. The claims join the Main Lithium zone and East Lithium zone claims and better surround and protect the East zone mineralized trends and extend the ground coverage more than 10 km to the East and Southeast. Ground work is planned for the new claims in the upcoming summer in search of new lithium discoveries.

Sartorius looks back on a very successful 2020 and expects further strong growth

Sartorius looks back on a very successful 2020 and expects further strong growth USA - English Outlook for the current year: sales projected to increase by 19 percent to 25 percent Accelerated and greater ramp-up of production capacities in all geographies; CAPEX ratio of 15 percent expected for 2021 Group management raises sales target for 2025 to about 5 billion euros Creation of more than 1,000 new jobs on average per year News provided by Share this article Share this article GOTTINGEN, Germany, Feb. 18, 2021 /PRNewswire/ The life science group Sartorius confirmed its preliminary figures for 2020 upon the release of its annual report. Group sales revenue surged by 30.2 percent to nearly 2,336 million euros in constant currencies (reported: +27.8 percent). Order intake

RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204

Share this article Share this article TEL AVIV, Israel and RALEIGH, N.C., Feb. 18, 2021 /PRNewswire/ RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today announced agreements with Cosmo Pharmaceuticals NV (SIX: COPN) ( Cosmo ) to manufacture two key products; RedHill s largest selling product in the U.S., Movantik ®, and RHB-204, currently in a Phase 3 U.S. study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease. Movantik is currently our biggest commercial product. This agreement strengthens our qualified supply base and capacity moving forward and solidifies our ongoing strategic relationship with Cosmo,

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.